Review of therapeutic effects

Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential

Volumn , Issue , 2013, Pages 123-142

  Grotenhermen, Franjo ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85071777877     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (27)

1. Association for Cannabis as Medicine, ed. Cannabis und Cannabinoide als Medizin. Congress repOlt (in German). Cologne: Nova-Institute, 1998
2. Barsch G. Zur therapeutischen Anwendung von Cannabis: Ergebnisse einer Pilotstudie unter HIV-positiven und Aids-kranken Miinnem und Frauen. In Deutsche Aids Hilfe, ed. Cannabis als Medizin. Beitriige aufeiner Fachtagung zu einem driingenden Thema, pp, 15-22, Berlin: Aids-Forum D.A.H, 1996
3. British Medical Association Therapeutic uses ofcannaNs. Amsterdam: Harwood Academic Publishers, 1997
4. Clifford DB. Tetrahydrocannabinol for tremor in multiple sclerosis. Annals afNeurology 1983;13(6):669-671
5. Consroe P, Musty R, Rein J, Tillery W, Pertwee R. The perceived effects of smoked cannabis on patients with multiple sclerosis. European Neurology 1997;38( 1): 44-48
6. Consroe P, Tillery W, Rein I, Musty RE. Reported Marijuana effects in patients with spinal cord injury. In 1998 Symposium on the Cal1nabinoids. Burlington, VT: International Cannabin aid Research Society, 1998, p. 64
7. Dansak DA. As an antiemet.ic and appetite stimulant in cancer patients. In Mathre ML, ed. Cannabis in medical practice: A legaL, historical and pharmacological overview of the therapeutic use of mariJuana. Jefferson, NC: McFarland & Co, 1997, pp. 69-83
8. Grinspoon L, Bakalar JB. The use of cannabis as a mood stabilizer in bipolar disorder: Anecdotal evidence and the need for clinical research. Journal ofPsychoactive Drugs 1998;30(2): 171-177
9. Grinspoon L, Bakalar JB. Marihuana, the forbidden medicine. New Haven, CT: Yale University Press, 1993
10. Grotenhermen F, Huppertz R. Hanf als Medizin: Die Wiederentdeckung einer Heilpflanze. Heidelberg: Haug-Verlag, 1997
11. Helliwell D. GPs are key informants in medicinal cannabis survey. GP Speak, Newsletter of the Northern Rivers Division of General Practice, April 1999, pA
12. House of Lords Select Committee on Science and Technology. Cannabis: The scientific and medical evidence. London: The Stationery Office, 1998
13. loy IE, Watson SI, Benson lA, eds. Marijuana and medicine: Assessing the science base. Washington, DC: Institute of Medicine, National Academy Press, 1999
14. Lancz G, Specter S, Brown HK. Suppressive effect of delta-9-tetrahydrocannabinol on herpes simplex virus infectivity in vitro. Proceedings of the Society for Experimental Biology and Medicine 1991;196(4):401-404
15. Mathre ML, ed. Cannabis in medical practice: A legal, historical and plwrmacaloglcal overview of the therapeutic use of marUuana. Iefferson, NC: McFarland & Co, 1997
16. Mechoularn R, ed. Cannabinoids as therapeutic agents. Boca Raton, FL: CRC Press, 1986
17. Mikuriya TH. Cannabis substitution. An adjunctive therapeutic tool in the treatment of alcoholism. Medical Times 1970:98(4): 187-191
18. Muller-Yahl KR, Kolbe H, Dengler R. Gilles de la Tourette-Syndrom. EinfluB von Nikotin, Alkohol und Marihuana auf die klinische Symptomatik. Nervenarzt 1997;68:985-989
19. Nok AJ, Ibrahim S, Arowosafe S, Longdet I, Ambrose A, Onyenekwe PC, WhOllg CZ. The trypanocidal effect of Cannabis sativa constituents in experimental animal trypanosomiasis. Veteriny' and Human Toxicology 1994;36(6):522-524
20. Noyes R, Baram DA. Cannabis analgesia. Comprehensive Psychiatry 1974; 15(6):531-535
21. Peralta V, Cuesta MI. Intluence of cannabis abuse on schizophrenic psychopathology. Acta Psychiatrica Scandinavica 1992;85(2): 127-130
22. Plasse TF. Gorter RW. Krasnow SH. Lane M. Shepard KY. Wadleigh RG. Recent clinical experience with dronabinol. Pharmacology, Biochemistry and Behavior 1991 ;40(3):695-700
23. Schnelle M, Grotenhennen F, Reif M, Gorter RW. Ergebnisse einer standardisierten Umfrage zur medizinischen Verwendung von C31mabisprodukten im deutschen Sprachraum, LResults of a standardized survey on the medical use of cannabis products in the Gennan-speaking areal. Forschende Komplementarmedizin (Research in Complementary MedicinelI999;(SuppI3): 2R-36
24. Schneier FR, Siris SG. A review of psychoactive substance use and abuse in schizophrenia: Pattems of drug choice. Journal of Nervous and Mental Disease 1987; 175(11):641-652
25. TNO Preventie en Gezondheid. Aard en omvang van Cannabis gebruik bij mensen met Multiple Sclerose. JA Deft, The Netherlands: TNO 1998
26. Yolicer L. Stelly M. Morris J. McLaughlin J. Volicer BJ. Ellects of dronabinol on anorexia and disturbed behavior in patients with Alzheinler's disease. InternationalJournal of Geriatric Psychiatry 1997; 12(9):913-919
27. 1-tetrahydrocannabinol administered by aerosol of asthmatic patients. Thorax 1976;31 (6):720-723